GBT Global Blood Therapeutics Inc.

-0.95  -2%
Previous Close 52.11
Open 52.2
Price To Book 5.66
Market Cap 2672212040
Shares 52,232,448
Volume 172,393
Short Ratio
Av. Daily Volume 1,160,102

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a discontinuation announced October 23, 2017 due to lack of efficacy.
Hypoxemia in patients with idiopathic pulmonary fibrosis (IPF) who are on supplemental oxygen at rest
Pre-NDA meeting scheduled for 1Q 2019. NDA to be filed under accelerated approval.
Sickle cell disease
Phase 2 data to be presented at ASH December 3, 2018 noted 55% (6 of 11) achieved a hemoglobin response >1 g/dL .
Sickle cell disease - children age 6-17.

Latest News

  1. GBT Launches ACCEL Grants Program to Improve Access to Care for People with Sickle Cell Disease
  2. Why Global Blood Therapeutics Surged 16.7% Higher in January
  3. GBT Announces New Employment Inducement Grants
  4. 6 Biotech Stocks to Watch Now
  5. GBT Announces Publication of Data from Phase 1/2 Study of Voxelotor in Patients with Sickle Cell Disease
  6. Should You Sell CRISPR Therapeutics Following an Analyst Downgrade?
  7. GBT to Present at the 37th Annual J.P. Morgan Healthcare Conference
  8. GBT Appoints Dawn Svoronos to Board of Directors
  9. Ghost Tree Capital’s AUM, Returns and Holdings
  10. Top 6 Performing IPOs of 2015 (ONCE, GBT)
  11. Here's Why Global Blood Therapeutics Fell 10.1% in November, Then Jumped 37% Since
  12. Global Blood Therapeutics, Voxelotor in Advanced Clinicals, Analysts Review and Target
  13. Global Blood Therapeutics Prices a $150.0 Million Common Stock Public Offering
  14. The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut
  15. 3 Biotech Stocks That Could Explode Higher in 2019
  16. Global Blood Therapeutics Announces Proposed Public Offering of Common Stock
  17. 3 Top Stocks After #ASH18
  18. Jim Cramer Advises His Viewers On Adobe, Barnes & Noble And More
  19. Cramer's lightning round: Barnes & Noble's stock is trading like it could get acquired